285 related articles for article (PubMed ID: 15579030)
1. Von Hippel-Lindau disease.
Maher ER
Curr Mol Med; 2004 Dec; 4(8):833-42. PubMed ID: 15579030
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.
Maher ER; Webster AR; Richards FM; Green JS; Crossey PA; Payne SJ; Moore AT
J Med Genet; 1996 Apr; 33(4):328-32. PubMed ID: 8730290
[TBL] [Abstract][Full Text] [Related]
3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
4. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
Iida K; Okimura Y; Takahashi K; Inomata S; Iguchi G; Kaji H; Chihara K
Int J Mol Med; 2004 Mar; 13(3):401-4. PubMed ID: 14767570
[TBL] [Abstract][Full Text] [Related]
5. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
Prowse AH; Webster AR; Richards FM; Richard S; Olschwang S; Resche F; Affara NA; Maher ER
Am J Hum Genet; 1997 Apr; 60(4):765-71. PubMed ID: 9106522
[TBL] [Abstract][Full Text] [Related]
6. [Von Hippel-Lindau disease].
Shuin T; Ashida S; Yao M; Kanno H
Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
[TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
Decker HJ; Weidt EJ; Brieger J
Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
10. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
11. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene.
Stolle C; Glenn G; Zbar B; Humphrey JS; Choyke P; Walther M; Pack S; Hurley K; Andrey C; Klausner R; Linehan WM
Hum Mutat; 1998; 12(6):417-23. PubMed ID: 9829911
[TBL] [Abstract][Full Text] [Related]
12. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
13. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas.
Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN
Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma.
Crossey PA; Eng C; Ginalska-Malinowska M; Lennard TW; Wheeler DC; Ponder BA; Maher ER
J Med Genet; 1995 Nov; 32(11):885-6. PubMed ID: 8592333
[TBL] [Abstract][Full Text] [Related]
15. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
[TBL] [Abstract][Full Text] [Related]
16. Von Hippel-Lindau disease and endocrine tumour susceptibility.
Woodward ER; Maher ER
Endocr Relat Cancer; 2006 Jun; 13(2):415-25. PubMed ID: 16728571
[TBL] [Abstract][Full Text] [Related]
17. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
[TBL] [Abstract][Full Text] [Related]
18. Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.
Zatyka M; Morrissey C; Kuzmin I; Lerman MI; Latif F; Richards FM; Maher ER
J Med Genet; 2002 Jul; 39(7):463-72. PubMed ID: 12114475
[TBL] [Abstract][Full Text] [Related]
19. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
20. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
